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Background: The older dialysis population is increasing, and several studies have investigated the effect of actual
age on the relationship between clinical parameters or clinical practice and prognosis. There is concern that
biological age does not necessarily reflect the actual effects of aging, and it is important to take heterogeneity
into account when considering the older population. In this study, we investigated whether such heterogeneities
exist in a large number of clinical parameters and how any disparities might be affected by the domains of
clinical indices.
Methods: We investigated the published, summarized results of the Japanese Society for Dialysis Therapy Renal
Data Registry, a nationwide survey of the Japanese dialysis population, for the year 2013.
Results: The potential population comprised 306,925 dialysis patients. We investigated coefficient of variations
(CVs) of 25 clinical indices across age groups and compared them with the CVs of the 45–59 years age group as
a reference group, using tests for homogeneity of variances. Almost all variables showed some heterogeneity by
age. The domain for muscle mass or visceral protein exhibited greater heterogeneity in older patients, but
surprisingly, the domain for body mass or physique exhibited less heterogeneity. The mean values of most
parameters declined in the older population.
Conclusions: This study demonstrated that variations exist in clinical indices in the older dialysis population.
Apart from biological age, we should take these heterogeneities into account when interpreting the findings of
clinical studies involving older dialysis patients and in their individualized management.
Keywords: Aging phenotype, Biological age, Coefficient of variances, Heterogeneity, Older patients, WastingBackground
The dialysis population has become much older in recent
years, and the proportion of elderly patients is increasing
in many registries [1, 2]. There are several clinical prob-
lems to overcome in the older hemodialysis population.
One of the most important involves malnutrition-related
syndromes, such as sarcopenia [3], protein energy wasting
[4], and frailty [5]. These syndromes are in fact associated
with a worse prognosis in the dialysis population as a
whole [6, 7]; these phenotypes are considered to be most
important in the management of the older population.* Correspondence: hanafusa@kc.twmu.ac.jp
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(http://creativecommons.org/publicdomain/zeStrategies against complications for older dialysis
patients sometimes differ from those for their younger
counterparts [8]. However, the definition of “older”
patients varies in different reports [9–11]. The reason
for this may be due to the heterogeneity among the
elderly population in terms of phenotype. Some patients
look younger than their actual age, while some look
older. Moss et al. reported that the “surprise” question,
“Would I be surprised if this patient died in the next
year?” correlated well with 1 year survival [12], indicat-
ing that the phenotype, presumably wasting or malnutri-
tion, seems important for survival.
We speculated that such phenotype of the “older”
population does matter and that it is important to take
the heterogeneities of such patients into account, whichle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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been no reports on the heterogeneity of the elderly
population. Therefore, here, we focused on the hetero-
geneity of the older dialysis population and investigated
which clinical indices exhibited large heterogeneity and
were potentially related to a poor prognosis, using
national registry data compiled by the Japanese Society
for Dialysis Therapy (JSDT). It is anticipated that our re-
sults will help the clinician to undertake individualized
management of older dialysis patients.
Methods
Population
Data from the annual Japanese Society for Dialysis Ther-
apy Renal Data Registry (JRDR) survey run by JSDT were
used for this analysis. The details of this registry have been
described previously [13]. We analyzed the data collected
in 2013. The summarized tables are recorded in CD-ROM
or are reported on the internet. In this analysis, we used
data that appears on JSDT’s website [14].
The potential population for this study was the entire dia-
lysis population as of December 31, 2013, namely 306,925
patients. The population was divided by 15-year age groups.
We excluded patients with missing data on age (n = 12)
and patients who were younger than 15 years (n = 116).
Clinical indices
The following clinical indices were investigated: (1)
mineral and bone disorder markers (corrected calcium
and phosphate); (2) malnutrition-related factors (total
cholesterol, high-density lipoprotein (HDL) cholesterol,
non-HDL cholesterol, percent creatinine generation rate
(%CGR) [15], normalized protein catabolic rate (nPCR)
[16], and albumin); (3) body mass and volume status
(body height, postdialytic body weight (BW), body mass
index (BMI), BW change, and fractional BW change); (4)
dialysis prescription and its consequences (dialysis dur-
ation, spKt/V [16], eqKt/V [17], blood flow rate, predia-
lytic blood urea, and creatinine); (5) circulatory factors
(systolic blood pressure, diastolic blood pressure, and
pulse rate); and (6) other factors (hemoglobin (Hb) level,
glycoalbumin, and HbA1c). Postdialytic BW, dialysis
duration, and blood flow rate were investigated among
the patients who were treated by hemodialysis, hemodia-
filtration, or hemoperfusion. The values of%CGR, nPCR,
BW change, fractional BW change, spKt/V, eqKt/V, and
creatinine were investigated only in patients who were
treated by hemodialysis, hemodiafiltration, or hemo-
perfusion three times weekly with a dialysis history
of ≥2 years. Glycoalbumin and HbA1c were investi-
gated among those who had history of diabetes or
were on glucose-lowering therapies. Parameters other
than those described above were studied in the en-
tire dialysis population.Statistical analysis
This analysis consists of two parts: one is to determine
the heterogeneities of age populations, and the other is
to compare them with the standard of 45–59 year-old
group.
The heterogeneity was measured by coefficient of
variations (CV) in this analysis, because standard devi-
ation (SD) does not necessarily express the degree of
heterogeneity when the averages vary. The tables of
the JRDR summarized data give the number of pa-
tients and mean values and SD for each parameter in
all age groups. CVs were calculated by dividing the SD
by the mean for each age category. The larger CV is
more heterogenic or heteroscedastic the population
can be considered.
Relative CVs were calculated by dividing the CVs of
each age group by that of the 45–59 years age group. If
the value is larger than one, the index is more hetero-
genic in older population than the younger counterpart.
Relative means were also calculated as the ratio of the
mean of each age group to that of the 45–59 years age
group, similarly to relative CVs.
Finally, we statistically compared the heterogeneities
across age groups by investigating the homogeneity of
variances. In details, we calculated variances by squaring
standard deviations. The tests for homogeneity of vari-
ances were performed on the squared relative CVs using
Bartlett’s test among overall groups and F tests for each
pair of age groups. The former investigated the homo-
geneity of the variances by age groups as a whole. When
the test indicated statistical significance, it shows that
the clinical index is heterogenic across age groups. On
the other hand, the latter tested statistical significance
by comparing the CV of each age group with that of
the reference group of ages 45–59. When a test was
significant, it indicates that the clinical index is more
heterogenic in that age group compared to that in the
45–59-year-old age group. Post hoc adjustment for
multiple comparisons was done by Bonferroni correc-
tion. The p values less than 0.05 were considered sig-
nificant. For multiple comparisons, p values less than
0.01 were considered significant because five pairs of
comparisons were performed with the 45–59 years age
group as the reference group. All statistical calculations
and analyses were performed using Microsoft Excel
2013 (Microsoft Corporation, Redmond, WA).
Ethical issues
This study is the secondary analyses of the summarized
and published data and does not deal with any personal
information. Therefore, we consider that this study is
deemed exempt from the Institutional Review Board or
Ethics Committee approval. This study adhered to the
Declaration of Helsinki.
Hanafusa et al. Renal Replacement Therapy  (2017) 3:1 Page 3 of 9Results
The demographics and characteristics of the total popu-
lation who underwent dialysis therapy in 2013 are shown
in Table 1 [1]. Mean age was 67.21 ± 12.51 years (mean
± SD). The age groups 15–29, 30–44, 45–59, 60–74, 75–
89, and ≥90 years accounted for 0.37, 4.91, 18.56, 45.87,
28.72, and 1.54% of the total population, respectively.
Table 2 shows the number of patients and their pro-
portion of sex, vintage, and primary diagnoses for each
age category. In the older age groups, there was a higher
proportion of female patients and a higher proportion of
patients with the primary diagnosis of nephrosclerosis;
less predominant were the proportion of patients with a
long history of dialysis and the proportion with diabetes
as the primary diagnosis.
Table 3 shows the SDs and means of the variables in-
vestigated as well as the number of the patients. Table 4
shows the CVs relative to those of the 45–59 years age
group, which is used as the reference group. The overall
differences of variances, including chi-square values and
p values calculated with the Bartlett test, are shown, as
well as p values for the differences of variances of the
age groups, taking the variance of the 45–59 years age
group as the references. For almost all variables, the var-
iances differed by age group. However, the trends them-
selves differed by index. We can categorize these indices
according to the relative CV for the 75–89 years age
group into four categories: (1) relative CVs of more than
1.1 (indicating the most heteroscedastic indices), namely
for %CGR, albumin, creatinine, fractional BW reduction,
blood urea nitrogen, and diastolic blood pressure; (2)Table 1 Background characteristics of the patients
Number of patients 306,925
Sex (male/female) 194,965/111,960
Age (mean ± SD) 67.21 ± 12.51
Vintage (years, number of patients, %)
<2 68,475 (22.3)
2–4 76,589 (25.0)
5–9 77,197 (25.2)
10–14 39,490 (12.9)
15–19 20,874 (6.8)
20–24 11,421 (3.7)
25–29 6611 (2.2)
30+ 6155 (2.0)
Primary diagnoses (numbers, %)
Diabetes 115,484 (37.6)
Glomerulonephritis 99,492 (32.4)
Nephrosclerosis 26,569 (8.7)
Polycystic kidney 10,683 (3.5)
Others or unknown 54,697 (17.8)relative CVs of 1.0–1.1 (mildly heterogeneous), namely
for phosphate, total cholesterol, nPCR, body height, BW
reduction, blood flow rate, systolic blood pressure, pulse
rate, and Hb; (3) relative CVs of 0.9–1.0 (less heteroge-
neous), namely for corrected calcium, non-HDL, HDL,
session duration, spKt/V, and eqKt/V; and (4) relative
CVs of less than 0.9 (least heterogeneous), namely for
BW, BMI, glycoalbumin, and HbA1c.
Figure 1 indicates that the disparities in representative
indices between several domains differ significantly
across the age groups. The relative CVs of indicators
relating to the muscle mass or visceral proteins increased
steadily with age, becoming more heteroscedastic. The
parameters related to dietary intake showed a modest
relationship across the age groups. On the other hand,
indices of body mass demonstrated that the dispersion
progressively decreased with the age of the population.
Figure 1 was designated to demonstrate the CVs by
themselves so that the heteroscedasticity can be recog-
nized easily. On the other hand, the CVs were calculated
from the SDs and means. The means are also subjected
to change by age groups, and the relative means indicate
the trend of the distributions of the absolute values as a
whole by age groups. Therefore, in Fig. 2, we added the
information about the relative means to the results
shown in Fig. 1 so that information about whether the
absolute values tended to become smaller among the
older population as well as the information about the
heteroscedasticity. This figure indicates that the mean
values of all indices included in Fig. 1 were lower in the
older age groups, irrespective of relative CVs. This fact
might indicate that the normal aging process accompan-
ies universal declines in clinical indices.
Discussion
Heterogeneity as determined by CV increased with age
in some domains, especially that of muscle mass or
visceral proteins. However, in some other domains such
as body mass, the disparities seem to be diminished in
the older population. This is the first study investigating
the heteroscedasticity of clinical indices, using nation-
wide registry data.
There were differences among the domains of indices;
factors related to sarcopenia or wasting were most prom-
inently dispersed. Moreover, the mean values of these
parameters declined with age. Therefore, muscle mass and
albumin level generally decreases with age, but their speed
of decline varies among individuals. The decrease in these
parameters, as discussed above, reportedly relates to poor
survival relating to wasting [6, 7]. Therefore, the hetero-
geneity of these clinical indices might reflect the diversity
of the older population in terms of “old” phenotypes and
relate to a worse prognosis. Moreover, the mean values of
CGR and albumin decreased less in older population,
Table 2 Patient characteristics by age group
Age groups 15–29 30–44 45–59 60–74 75–89 90+
Sex
Male 749 (66.8) 10,315 (68.4) 38,610 (67.8) 91,189 (64.8) 51,997 (59.0) 2032 (42.9)
Female 372 (33.2) 4756 (31.6) 18,340 (32.2) 49,583 (35.2) 36,150 (41.0) 2704 (57.1)
Vintage (years, number of patients, %)
<2 383 (34.2) 3556 (23.6) 11,484 (20.2) 28,358 (20.2) 23,464 (26.6) 1163 (24.6)
2–4 323 (28.8) 3756 (24.9) 12,996 (22.8) 32,734 (23.3) 25,177 (28.6) 1565 (33.1)
5–9 263 (23.5) 3564 (23.7) 13,807 (24.3) 35,296 (25.1) 22,800 (25.9) 1447 (30.6)
10–14 103 (9.2) 2134 (14.2) 7782 (13.7) 19,446 (13.8) 9598 (10.9) 425 (9.0)
15–19 34 (3.0) 1176 (7.8) 4673 (8.2) 10,882 (7.7) 4007 (4.5) 102 (2.2)
20–24 11 (1.0) 605 (4.0) 2890 (5.1) 6174 (4.4) 1715 (1.9) 26 (0.5)
25–29 4 (0.4) 206 (1.4) 1734 (3.0) 3890 (2.8) 774 (0.9) 3 (0.1)
30+ 0 (0.0) 69 (0.5) 1564 (2.7) 3948 (2.8) 572 (0.6) 2 (0.0)
Primary diagnoses (numbers, %)
Diabetes 61 (5.4) 4268 (28.3) 21,653 (38.0) 57,903 (41.1) 30,672 (34.8) 920 (19.4)
Glomerulonephritis 389 (34.7) 5635 (37.4) 20,180 (35.4) 46,654 (33.1) 25,273 (28.7) 1344 (28.4)
Nephrosclerosis 34 (3.0) 614 (4.1) 2411 (4.2) 8917 (6.3) 13,311 (15.1) 1279 (27.0)
Polycystic kidney 21 (1.9) 433 (2.9) 2738 (4.8) 5373 (3.8) 2050 (2.3) 63 (1.3)
Others or unknown 615 (54.9) 4119 (27.3) 9967 (17.5) 21,917 (15.6) 16,832 (19.1) 1130 (23.9)
The number of patients (percentage) in each age group is shown. Patients with missing or unknown values for age or background characteristics were excluded.
Therefore, the sum of the numbers is not equal to the total population shown in Table 1
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might reflect that CGR and albumin are less affected by
aging and they could be good markers of aging phenotype.
In this analysis, we investigated the disparity in muscle
mass in terms of CGR. However, muscle strength is
reported to relate to survival to a greater degree [6]. The
concept of dynapenia has been proposed [18, 19]. Future
studies investigating the heterogeneity of muscular
strength and its relation to survival are required.
Albumin has been used as a marker of malnutrition, but
many other factors also affect albumin levels [20]. Dietary
restriction only does not decrease the albumin level and it is
now regarded as a factor of wasting [20]. The 2013 annual
JRDR survey, the source of the data analyzed in this study,
also investigated C-reactive protein (CRP). However, the
distribution of CRP does not follow a normal distribution,
and its heterogeneity cannot be assessed by SD or CV as we
performed on other variables because the variables that do
not follow normal distribution cannot be summarized by
SDs or means. Therefore, we could not investigate the
heterogeneity of CPR, and we cannot draw the conclusion
that the disparity of albumin relates to inflammation status.
Dietary intake is reduced in the elderly population
because of reduced appetite [21]. Moreover, the degree
of appetite itself relates to prognosis [21]. In this study,
we used nPCR as a surrogate of dietary intake. On the
other hand, phosphate is contained in foods that contain
much protein [22]. Phosphate binders and dialysisdosage, especially session length, also affect the level of
phosphate [22]. It is interesting to note then that nPCR
and phosphate exhibited similar trends. Intradialytic BW
reduction can be related to sodium intake during inter-
dialytic periods [23], which also followed a similar trend
to that of nPCR and phosphate levels. Therefore, these
clinical indices can be considered as surrogate markers
of dietary intake in patients.
Surprisingly, the distribution of body mass tended to
be smaller in the older population even though the dis-
parities of muscle mass become wide among the elderly
population. An inverse relationship can be observed in
the dialysis population [24]; patients with larger BMI
experience better survival [25]. However, in the Asian
population, such relationship might be weaker than in
the white or black populations [25]. Female patients tend
to have better survival among the Japanese population,
and the average age of female patients is higher than
their male counterparts [1]. Actually, Table 2 shows that
the proportion of female patients was larger among the
older age groups. Obviously, female patients have a
smaller physique than male patients. Therefore, the
present results might be attributed to the predominance
of female patients in the older age groups. On the other
hand, it is possible that the findings of the smaller and
relatively homogeneous physique in older patients merely
reflect the trend in the general population because this
study did not examine variances in the general population.
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Fig. 1 Heterogeneity of representative clinical parameters by age group. The figure shows the trends in relative coefficient of variations (CV) (i.e.,
the CV of the 45–59 years age group was set as 1) for the clinical parameters related to a muscle mass or visceral proteins, b dietary intake, and
c body mass or physique. The CVs for indices of muscle mass or visceral proteins became larger among the older population, whereas the CVs
for those of body mass became smaller. Indices for dietary intake tended to be dispersed in the very old population. CV coefficient of variance,
%CGR percent creatinine generation ratio, a surrogate marker of muscle mass, Cr creatinine, Alb albumin, nPCR normalized protein catabolic rate,
BW body weight, BMI body mass index, ref reference
Fig. 2 Evolution of the relationship between mean and SD for representative indices among age groups ≥45 years. The relationship between the
set of relative coefficients of variations (CV) and relative mean values are shown. The 45–59 years age group was set as a standard for both CV and
means. The mean of all the indices decreased to a large degree in the older population. Each point indicates the age groups of 45–59, 60–74, 75–89,
and ≥90 years. Open circles, %CGR; open squares, Alb; open triangles, Cr; closed circles, nPCR; closed squares, phosphate; closed triangles, body weight
reduction; gray circles, body weight; and gray squares, body mass index
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Hanafusa et al. Renal Replacement Therapy  (2017) 3:1 Page 8 of 9Moreover, there was a discrepancy in terms of heterosce-
dasticity between the indices regarding body mass such as
BMI or BW and the indices regarding muscle mass such as
%CGR or creatinine. The former showed to be less hetero-
genic, while the latter showed to be more heterogenic in
older population. BMI is one of the simplest indices to
describe the physiques. However, it cannot distinguish fat
mass from muscle mass. The dialysis patients are shown to
reduce muscle mass, while they often lose less amount of
fat or even gain it during the course of dialysis therapy [26].
Therefore, BMI can underestimate the changes in muscle
mass [27]. This point might cause the discrepancy of
heteroscedasticity between body mass and muscle mass.
On the other hand, body height can contribute to BMI.
However, as Table 4 shows, the heterogeneity of height
remained small even in the older population. Moreover, the
mean values of body height were less in older population.
Several recent studies demonstrated that taller dialysis pa-
tients might experience worse survival [28, 29]. Thus, the
smaller and less heterogenic older population in terms of
their body height might be due to the survival effects partly.
Nonetheless, we should pay attention to the clinical
indices which exhibited large heterogeneity, such as
creatinine generation rate, creatinine, and albumin, when
we perform clinical practice on the older population.
The deterioration of these indices might reflect the
degree of the morbid conditions among older popula-
tion. Future study will be required to investigate the
relationship to the clinical outcomes, such as mortality,
quality of life (QOL), and activity of daily living (ADL).
After that, the interventions to the indices are warranted
to improve the outcomes of the patients.
This study has several limitations. The first is its
cross-sectional and observational nature. Therefore, we
cannot draw any conclusions about the time course or
cause-effect relationship. The second is that this study
was based on results that appeared in summarized
tables, and therefore, detailed investigations, such as
further stratification by sex or primary diagnoses, could
not be performed. The third is that the data that we used
did not contain the data for clinical outcomes. There-
fore, we could not investigate the effect of heterogeneity
observed on mortality, QOL, or ADL. The fourth is that
the JRDR data were almost exclusively derived from
Japanese people. Therefore, the applicability of our findings
to other ethnicities is unclear. Lastly, data was missing on
some parameters in some patients. Although the number
of the patients was sufficiently large, which is the most
important advantage of this study, it is possible that
errors exist.
Although there are several limitations in this study,
the strengths of this study are the large number of
patients and parameters that were examined. These
results may contribute to the individualized managementof the older dialysis population. Further studies on the
cause of disparities and the relationship to the prognosis
of the patients are required. We anticipate that the find-
ings of such studies will provide a better understanding
of phenotypes in the older dialysis population.
Conclusions
This is the first study to investigate heterogeneity in the
older dialysis population. There were some disparities in
heterogeneity across the parameters. Clinical parameters
related to muscle mass or wasting exhibited larger hetero-
geneity, while those related to body mass or BW exhibited
less heterogeneity. Individualized management for older
dialysis patients with these heterogeneities might contrib-
ute to better outcomes in this population.
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